65,437 trials
Nervous System Diseases
Primary: Efficacy: Number of Participants With Therapeutic Success — 3 Participants
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) at Week 26 — 2865.43; 2817.08; -31.29; -79.47 mL — p=0.495
Healthy Marriage · Healthy Relationship
Primary: Couple Satisfaction Index — 4.82; 4.90; 4.78 score on a scale — p=.005
Joint Disease · Arthropathy
Primary: Visual Analog Scale (VAS) for Pain — 4.53; 4.48; 4.54 score on a scale
Myelofibrosis
Primary: Percentage of Participants With Spleen Response — 0; 10.2 percentage of participants
Ulcerative Colitis
Primary: Proportion of Subjects With Remission at Month 6 — 82; 67 Participants — p=>0.05
Psoriatic Arthritis
Primary: Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Score at Month 1
Hepatitis C · Medication Adherence
Primary: HCV Treatment Adherence — 83; 100; 88 percent of medication taken
Traumatic Brain Injury
Primary: Level of Simulator Sickness [Feasibility and Safety] — 0.16; 0.03 score on a scale
Stroke · Hemiparesis
Primary: Wolf Motor Function Test — -0.38; -0.24; -0.29; -0.22 natural log of performance time change
Scoliosis
Primary: Scoliosis Research Society Quality of Life Questionnaire (SRS QOL) Subscore — 0.5; 0.5 score on a scale — p=<0.001
Schizophrenia
Primary: Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) — 5; 6; 9; 11 participants
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Colorectal Cancer
Primary: Participants Completing CRC Screening Per Electronic Medical Record Documentation — 37; 59; 27 Participants
COVID-19
Primary: Percentage of Participants Alive and Free of Respiratory Failure at Day 14 — 83.1; 90.9 Percentage of participants